This product is no longer promoted on Made-in-China.com. If you find any infringement or sensitive information of it, please contact us for handling. Thank you.
  • Westren Medicine Isosorbide Dinitrate Tablets 5mg Westren Pharma for Human
  • Westren Medicine Isosorbide Dinitrate Tablets 5mg Westren Pharma for Human

Westren Medicine Isosorbide Dinitrate Tablets 5mg Westren Pharma for Human

Contact Supplier

Diamond Member Since 2020

Suppliers with verified business licenses

Trading Company

Basic Info.

Model NO.
Tablets
Pharmaceutical Technology
Chemical Synthesis
Dosage
10mg
Use
Oral
Transport Package
Box
Specification
5mg
Origin
China
Production Capacity
500000box/Month

Product Description

About US
DMS is a leading pharmaceutical Contract Development and Manufacturing Organizations (CDMO).

DMS's Manufacturing Services supply several hundred different products in a variety of dosage forms including solid dose, semi solids, sterile (liquids, freeze dried,powder), beta-lactams, hormones, dry powder metered dose inhalers, oral liquids and granulates, from our facilities across the world.

WE CAN PROVIDE MAKE FORMEULATION (OEM)

:0086-133-3193-6656

Product Name
Isosorbide Dinitrate Tablets
Contains
IIsosorbide Dinitrate 5mg;Isosorbide Dinitrate 10mg
Package
100 tabletss/bottle
Store
store at 20-25°C (68-77°F)
Application
relaxation of vascular smooth muscle
CLINICAL PHARMACOLOGY
The principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Dilatation of the coronary arteries also occurs. The relative importance of preload reduction, afterload reduction, and coronary dilatation remains undefined.
Dosing regimens for most chronically used drugs are designed to provide plasma concentrations that are continuously greater than a minimally effective concentration. This strategy is inappropriate for organic nitrates. Several well-controlled clinical trials have used exercise testing to assess the anti-anginal efficacy of continuously-delivered nitrates. In the large majority of these trials, active agents were no more effective than placebo after 24 hours (or less) of continuous therapy. Attempts to overcome nitrate tolerance by dose escalation, even to doses far in excess of those used acutely, have consistently failed. Only after nitrates have been absent from the body for several hours has their anti-anginal efficacy been restored.
Pharmacokinetics
Absorption of isosorbide dinitrate after oral dosing is nearly complete, but bioavailability is highly variable (10% to 90%), with extensive first-pass metabolism in the liver. Serum levels reach their maxima about an hour after ingestion. The average bioavailability of ISDN is about 25%; most studies have observed progressive increases in bioavailability during chronic therapy.
Once absorbed, the distribution volume of isosorbide dinitrate is 2 to 4 L/kg, and this volume is cleared at the rate of 2 to 4 L/min, so ISDN's half-life in serum is about an hour. Since the clearance exceeds hepatic blood flow, considerable extrahepatic metabolism must also occur. Clearance is affected primarily by denitration to the 2-mononitrate (15 to 25%) and the 5-mononitrate (75 to 85%).
Both metabolites have biological activity, especially the 5-mononitrate. With an overall half-life of about 5 hours, the 5-mononitrate is cleared from the serum by denitration to isosorbide; glucuronidation to the 5-mononitrate glucuronide; and denitration/hydration to sorbitol. The 2-mononitrate has been less well studied, but it appears to participate in the same metabolic pathways, with a half-life of about 2 hours.
The daily dose-free interval sufficient to avoid tolerance to organic nitrates has not been well defined. Studies of nitroglycerin (an organic nitrate with a very short half-life) have shown that daily dose-free intervals of 10 to 12 hours are usually sufficient to minimize tolerance. Daily dose-free intervals that have succeeded in avoiding tolerance during trials of moderate doses (e.g., 30 mg) of immediate-r

Send your message to this supplier

*From:
*To:
avatar Mr. Kaide Kong
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

Contact Supplier

Diamond Member Since 2020

Suppliers with verified business licenses

Trading Company
Management System Certification
ISO 9001, ISO 9000, GMP
Import & Export Mode
Exportation Via Agency